Year |
Citation |
Score |
2024 |
Reynolds LM, Gulmez A, Fayad SL, Campos RC, Rigoni D, Nguyen C, Le Borgne T, Topilko T, Rajot D, Franco C, Fernandez SP, Marti F, Heck N, Mourot A, Renier N, et al. Transient nicotine exposure in early adolescent male mice freezes their dopamine circuits in an immature state. Nature Communications. 15: 9017. PMID 39424848 DOI: 10.1038/s41467-024-53327-w |
0.448 |
|
2023 |
Caldwell M, Ayo-Jibunoh V, Mendoza JC, Brimblecombe KR, Reynolds LM, Zhu Jiang XY, Alarcon C, Fiore E, N Tomaio J, Phillips GR, Mingote S, Flores C, Casaccia P, Liu J, Cragg SJ, et al. Axo-glial interactions between midbrain dopamine neurons and oligodendrocyte lineage cells in the anterior corpus callosum. Brain Structure & Function. PMID 37668732 DOI: 10.1007/s00429-023-02695-y |
0.723 |
|
2023 |
Reynolds LM, Hernandez G, MacGowan D, Popescu C, Nouel D, Cuesta S, Burke S, Savell KE, Zhao J, Restrepo-Lozano JM, Giroux M, Israel S, Orsini T, He S, Wodzinski M, et al. Amphetamine disrupts dopamine axon growth in adolescence by a sex-specific mechanism in mice. Nature Communications. 14: 4035. PMID 37419977 DOI: 10.1038/s41467-023-39665-1 |
0.675 |
|
2021 |
Dongelmans M, Durand-de Cuttoli R, Nguyen C, Come M, Duranté EK, Lemoine D, Brito R, Ahmed Yahia T, Mondoloni S, Didienne S, Bousseyrol E, Hannesse B, Reynolds LM, Torquet N, Dalkara D, et al. Chronic nicotine increases midbrain dopamine neuron activity and biases individual strategies towards reduced exploration in mice. Nature Communications. 12: 6945. PMID 34836948 DOI: 10.1038/s41467-021-27268-7 |
0.315 |
|
2021 |
Reynolds LM, Flores C. Mesocorticolimbic Dopamine Pathways Across Adolescence: Diversity in Development. Frontiers in Neural Circuits. 15: 735625. PMID 34566584 DOI: 10.3389/fncir.2021.735625 |
0.664 |
|
2020 |
Cuesta S, Nouel D, Reynolds LM, Morgunova A, Torres-Berrío A, White A, Hernandez G, Cooper HM, Flores C. Dopamine Axon Targeting in the Nucleus Accumbens in Adolescence Requires Netrin-1. Frontiers in Cell and Developmental Biology. 8: 487. PMID 32714924 DOI: 10.3389/Fcell.2020.00487 |
0.781 |
|
2019 |
Cuesta S, Restrepo-Lozano JM, Popescu C, He S, Reynolds LM, Israel S, Hernandez G, Rais R, Slusher BS, Flores C. DCC-related developmental effects of abused- versus therapeutic-like amphetamine doses in adolescence. Addiction Biology. e12791. PMID 31192517 DOI: 10.1111/Adb.12791 |
0.687 |
|
2018 |
Reynolds LM, Yetnikoff L, Pokinko M, Wodzinski M, Epelbaum JG, Lambert LC, Cossette MP, Arvanitogiannis A, Flores C. Early Adolescence is a Critical Period for the Maturation of Inhibitory Behavior. Cerebral Cortex (New York, N.Y. : 1991). PMID 30295713 DOI: 10.1093/Cercor/Bhy247 |
0.752 |
|
2018 |
Reynolds LM, Flores C. Guidance cues: linking drug use in adolescence with psychiatric disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30275561 DOI: 10.1038/S41386-018-0221-7 |
0.549 |
|
2018 |
Hoops D, Reynolds LM, Restrepo-Lozano JM, Flores C. Dopamine Development in the Mouse Orbital Prefrontal Cortex Is Protracted and Sensitive to Amphetamine in Adolescence. Eneuro. 5. PMID 29333488 DOI: 10.1523/ENEURO.0372-17.2017 |
0.714 |
|
2017 |
Cuesta S, Restrepo-Lozano JM, Silvestrin S, Nouel D, Torres-Berrio A, Reynolds LM, Arvanitogiannis A, Flores C. Non-Contingent Exposure to Amphetamine in Adolescence Recruits miR-218 to Regulate Dcc Expression in the VTA. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29154364 DOI: 10.1038/Npp.2017.284 |
0.741 |
|
2017 |
Reynolds LM, Pokinko M, Torres-Berrío A, Cuesta S, Lambert LC, Del Cid Pellitero E, Wodzinski M, Manitt C, Krimpenfort P, Kolb B, Flores C. DCC Receptors Drive Prefrontal Cortex Maturation by Determining Dopamine Axon Targeting in Adolescence. Biological Psychiatry. PMID 28720317 DOI: 10.1016/J.Biopsych.2017.06.009 |
0.769 |
|
2017 |
Madularu D, Mathieu AP, Kumaragamage C, Reynolds L, Near J, Flores C, Rajah MN. A non-invasive restraining system for awake mouse imaging. Journal of Neuroscience Methods. PMID 28634149 DOI: 10.1016/J.Jneumeth.2017.06.008 |
0.44 |
|
2015 |
Reynolds LM, Gifuni AJ, McCrea ET, Shizgal P, Flores C. dcc haploinsufficiency results in blunted sensitivity to cocaine enhancement of reward seeking. Behavioural Brain Research. PMID 26005129 DOI: 10.1016/J.Bbr.2015.05.020 |
0.755 |
|
2015 |
Reynolds LM, Makowski CS, Yogendran SV, Kiessling S, Cermakian N, Flores C. Amphetamine in adolescence disrupts the development of medial prefrontal cortex dopamine connectivity in a DCC-dependent manner. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1101-12. PMID 25336209 DOI: 10.1038/Npp.2014.287 |
0.737 |
|
2014 |
Engin E, Bakhurin KI, Smith KS, Hines RM, Reynolds LM, Tang W, Sprengel R, Moss SJ, Rudolph U. Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1805-15. PMID 24553732 DOI: 10.1038/Npp.2014.41 |
0.543 |
|
2013 |
Engin E, Bakhurin KI, Smith KS, Hines RM, Reynolds LM, Tang W, Sprengel R, Moss SJ, Rudolph U. S.6.1 - NEURAL BASIS OF BENZODIAZEPINE REWARD Behavioural Pharmacology. 24: e6-e7. DOI: 10.1097/01.Fbp.0000434704.76389.C2 |
0.527 |
|
2012 |
Reynolds LM, Engin E, Tantillo G, Lau HM, Muschamp JW, Carlezon WA, Rudolph U. Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2531-40. PMID 22763624 DOI: 10.1038/Npp.2012.115 |
0.568 |
|
1983 |
Reynolds LM, Dyer RG, Jenner P, Marsden CD. Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration. The Journal of Pharmacy and Pharmacology. 35: 170-4. PMID 6132975 DOI: 10.1111/J.2042-7158.1983.Tb04299.X |
0.373 |
|
1980 |
Reynolds GP, Reynolds LM, Riederer P, Jellinger K, Gabriel E. Dopamine receptors and schizophrenia: drug effect or illness. Lancet. 2: 1251. PMID 6108424 DOI: 10.1016/S0140-6736(80)92513-1 |
0.3 |
|
Show low-probability matches. |